Brachytherapy for the Treatment of Prostate Cancer
- 1 September 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Cancer Journal
- Vol. 13 (5), 302-312
- https://doi.org/10.1097/ppo.0b013e318156dcbe
Abstract
Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients. Largely due to patient lead advocacy for minimally invasive treatment options, high-quality prostate implants have become widely available in the US, Europe, and Japan. The reason that brachytherapy results are reproducible in several different practice settings is because numerous implant quality factors have been defined over the last 20 years, which can be applied objectively to judge the success of the intervention both during and after the procedure. In addition, recent long-term follow-up studies have clarified that the secondary cancer incidence of brachytherapy is not clinically meaningful. In terms of future directions, the study of radiation repair genetics may allow for the counseling physician to better estimate any given patients risk for side effects, thereby substantially reducing the therapeutic uncertainties faced by patients choosing a prostate cancer intervention.Keywords
This publication has 91 references indexed in Scilit:
- Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapyBrachytherapy, 2003
- Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapyBrachytherapy, 2003
- Brachytherapy or radical prostatectomy: is there a preferred method for treating localized prostate cancer?BJU International, 2003
- High and intermediate risk prostate cancer treated with three-dimensional computed tomography-guided brachytherapy: 2-8-year follow-up.Radiotherapy and Oncology, 2003
- Prostate gland motion and deformation caused by needle placement during brachytherapyBrachytherapy, 2002
- What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptomsBrachytherapy, 2002
- 10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapyInternational Journal of Radiation Oncology*Biology*Physics, 2001
- Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidanceInternational Journal of Radiation Oncology*Biology*Physics, 1998
- A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantationInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Transperineal 125 Iodine Seed Implantation in Prostatic Cancer Guided by Transrectal UltrasonographyJournal of Urology, 1983